Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 13/20 | 0.43 |
| ▸ | VEGFA | P15692 | 2/20 | 0.43 |
| ▸ | FLT1 | P17948 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | EGLN3 | Q9H6Z9 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.39 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.39 |
| ▸ | PTPRC | P08575 | 2/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.38 |
| ▸ | USP5 | P45974 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21783356 | 0.88 | ATM (0.40) | EGLN1VEGFAFLT1ATMEGLN3 | |
| SCHEMBL19698958 | 0.86 | GCG (0.43) | KDM4EALDH1A1HPGD | |
| SCHEMBL19705733 | 0.81 | EGLN1 (0.43) | EGLN1VEGFAFLT1ATMEGLN3 | |
| SCHEMBL25138292 | 0.81 | HDAC6 (0.50) | — | |
| SCHEMBL19698930 | 0.79 | GPBAR1 (0.40) | ATMKDM4EHPGDS | |
| SCHEMBL19725183 | 0.79 | EGLN1 (0.41) | EGLN1VEGFAFLT1ATMEGLN3 | |
| SCHEMBL19698928 | 0.79 | HCAR2 (0.43) | KDM4EALDH1A1 | |
| SCHEMBL19738292 | 0.78 | EGLN1 (0.40) | EGLN1VEGFAFLT1ATMEGLN3 | |
| SCHEMBL19117337 | 0.74 | MAPK14 (0.39) | KDM4EALDH1A1HPGDS | |
| SCHEMBL19105598 | 0.74 | HPGDS (0.41) | SMN1; SMN2HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739065-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739065-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20220204460-A1 | FXR (NR1H4) MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2022-06-30 | — | — | US | disclosed |
| EP-3587412-B1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2022-05-25 | — | — | EP | disclosed |
| US-10981881-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20200369632-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2020-11-26 | — | — | US | disclosed |
| US-20200361920-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2020-11-19 | — | — | US | disclosed |
| US-10774054-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20200071282-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2020-03-05 | — | — | US | disclosed |
| US-20190308962-A1 | FXR (NR1H4) Modulating Compounds | GILEAD SCIENCES, INC. (US) | 2019-10-10 | — | — | US | disclosed |
| US-10421730-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2019-09-24 | — | — | US | disclosed |
| EP-3257847-B1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2019-08-21 | — | — | EP | disclosed |
| WO-2017218330-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2017-12-21 | — | — | WO | disclosed |
| EP-3257847-A1 | FXR (NR1H4) MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2017-12-20 | — | — | EP | disclosed |
| US-20170355685-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355685-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190308962-A1 | FXR (NR1H4) Modulating Compounds | NR1H4, NR1H2, NR1H3 | EGLN1 4520/4885VEGFA 4691/4885FLT1 3553/4885 |
| US-10981881-B2 | FXR (NR1H4) modulating compounds | NR1H4, NR1H2, NR1H3 | EGLN1 4450/4885VEGFA 4586/4885FLT1 3477/4885 |
| US-11739065-B2 | FXR (NR1H4) modulating compounds | NR1H4, NR1H2, NR1H3 | EGLN1 4450/4885VEGFA 4586/4885FLT1 3477/4885 |
| US-10421730-B2 | FXR (NR1H4) modulating compounds | NR1H4, NR1H2, NR1H3 | EGLN1 4450/4885VEGFA 4586/4885FLT1 3477/4885 |
| US-20170355685-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | EGLN1 4450/4885VEGFA 4586/4885FLT1 3477/4885 |
| US-20200071282-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | EGLN1 4450/4885VEGFA 4586/4885FLT1 3477/4885 |
| US-20200369632-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | EGLN1 4450/4885VEGFA 4586/4885FLT1 3477/4885 |
| US-20200361920-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | SLC10A1, NR1H4, SLC10A2 | EGLN1 3272/4885VEGFA 4396/4885FLT1 3339/4885 |
| US-20220204460-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | EGLN1 4450/4885VEGFA 4586/4885FLT1 3477/4885 |
| US-10774054-B2 | FXR (NR1H4) modulating compounds | NR1H4, NR1H2, NR1H3 | EGLN1 4450/4885VEGFA 4586/4885FLT1 3477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.